Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clopidogrel: a novel antiplatelet agent.

S D'Sa1, S J Machin

  • 1Department of Haematology, University College Hospital, London.

Hospital Medicine (London, England : 1998)
|July 9, 1999
PubMed
Summary

Clopidogrel, a new antiplatelet drug, offers a unique mechanism compared to aspirin. It shows greater effectiveness than aspirin in preventing thrombotic events with fewer side effects than ticlopidine.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients.

Seminars in hematology·2023
Same author

Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus.

ESMO open·2022
Same author

A performance evaluation of a novel human recombinant tissue factor prothrombin time reagent (Revohem<sup>™</sup> PT).

International journal of laboratory hematology·2017
Same author

ICSH recommendations for modified and alternate methods measuring the erythrocyte sedimentation rate.

International journal of laboratory hematology·2017
Same author

Rivaroxaban limits complement activation compared with warfarin in antiphospholipid syndrome patients with venous thromboembolism.

Journal of thrombosis and haemostasis : JTH·2016
Same author

Recombinant Alpha 2A Interferon-An Effective Maintenance Agent in Essential Thrombocythaemia.

Leukemia & lymphoma·2016

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Thrombosis Research

Background:

  • Aspirin is a common antiplatelet agent.
  • Ticlopidine is another antiplatelet agent with known side effects.
  • There is a need for effective antiplatelet therapies with improved safety profiles.

Purpose of the Study:

  • To introduce clopidogrel as a novel antiplatelet agent.
  • To compare the efficacy and safety of clopidogrel with aspirin and ticlopidine.
  • To evaluate the potential of clopidogrel in reducing vascular mortality and morbidity.

Main Methods:

  • Mechanism of action of clopidogrel.
  • Comparative studies with aspirin and ticlopidine.
  • Evaluation of side-effect profiles.

Main Results:

  • Clopidogrel exhibits a different mechanism of action compared to aspirin.
  • Clopidogrel demonstrates greater efficacy than aspirin in preventing certain thrombotic events.
  • Clopidogrel possesses a safer side-effect profile than ticlopidine.

Conclusions:

  • Clopidogrel represents a significant advancement in antiplatelet therapy.
  • The drug is expected to enhance antithrombotic strategies.
  • Clopidogrel has the potential to reduce vascular mortality and morbidity beyond current treatments.

Related Experiment Videos